SeroCovid19 : prospective seroprevalence monitoring reveals substantially reduced SARS-CoV-2 infection rate among tertiary pediatric patients
Abstract
Background Coronavirus disease 2019 (COVID-19) is a clinically heterogeneous entity with several host, environmental, and viral risk factors identified to date. COVID-19 in children generally manifests asymptomatic or mild. Pediatric patients with chronic medical conditions are potentially at increased risk for severe COVID-19, although convincing data is lacking. Among these children, we aimed to study COVID-19 incidence and disease severity. Methods We initiated a prospective cohort study with longitudinal (every 3-6 months) quantification of serum SARS-CoV-2 IgG (Abbott) and questionnaires in pediatric patients (0-18y) with chronic medical conditions in follow-up at Ghent University Hospital, a tertiary referral center. This interim analysis incorporates inclusions from Nov 1, 2020 until Jan 14, 2021. Results Here, we present data of the first 250 included patients (mean age 10.4y). Chronic conditions required follow-up at departments of immunology (26.4%), nephrology (16.7%), rheumatology (15.4%), gastroenterology (14.5%), endocrinology (8.8%), pulmonology (8.8%) or others (9.3%). Chronic immunosuppressive drugs were used in 35.6%. Inborn errors of immunity, possibly affecting antibody responses, were present in 18.0%. Restriction from school or daycare centers (additional to general lockdown and school closures) was documented in 35.1% and 10.7%, before and after the summer break, respectively. Since the start of the pandemic, close contacts with proven COVID-19 were…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 250 participants or records.
Read the paper
Related studies
- 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
- Outpatient gatifloxacin therapy and dysglycemia in older adults
- Safety of fluoroquinolones
- 2019 ACCP Annual Meeting
- Comparative risk of serious hypoglycemia among persons dispensed a fluoroquinolone versus a non-fluoroquinolone antibiotic
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.